{"id":52135,"date":"2022-12-19T18:02:10","date_gmt":"2022-12-19T17:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neuroscience-antibodies-assays-global-market-to-reach-5-43-billion-by-2026-at-a-cagr-of-10-97-researchandmarkets-com\/"},"modified":"2022-12-19T18:02:10","modified_gmt":"2022-12-19T17:02:10","slug":"neuroscience-antibodies-assays-global-market-to-reach-5-43-billion-by-2026-at-a-cagr-of-10-97-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neuroscience-antibodies-assays-global-market-to-reach-5-43-billion-by-2026-at-a-cagr-of-10-97-researchandmarkets-com\/","title":{"rendered":"Neuroscience Antibodies & Assays Global Market to Reach $5.43 Billion by 2026 at a CAGR of 10.97% – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Neuroscience Antibodies & Assays Global Market Report 2022: Ukraine-Russia War Impact”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global neuroscience antibodies & assays market is expected to grow from $3.22 billion in 2021 to $3.58 billion in 2022 at a compound annual growth rate (CAGR) of 11.21%. The neuroscience antibodies & assays market is expected to reach $5.43 billion in 2026 at a compound annual growth rate (CAGR) of 10.97%.\n<\/p>\n

\nNorth America was the largest region in the neuroscience antibodies & assays market in 2021. The regions covered in neuroscience antibodies & assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.\n<\/p>\n

\nThe increasing incidents of neurological illnesses across the globe are expected to propel the growth of the neuroscience antibodies & assays market going forward. Neurological illnesses are disorders affecting the nervous system and examples of neurological disorders include epilepsy, Alzheimer’s disease, dementia and so on. The rise in the number of neurological illnesses requires more research and development activities for the treatment of these diseases.\n<\/p>\n

\nAntibodies and assays are used in research and development activities to study development, systems, structure and function, and disorders and degeneration of the nervous system. Thus, the neuroscience antibodies & assays market grows with the increase in incidents of neurological illnesses.\n<\/p>\n

\nFor instance, According to World Health Organization, a Switzerland-based health promotion agency 55 million people live with dementia globally, and there are nearly 10 million new cases every year as per 2021 data. According to Alzheimer’s Association a US based Non-profit association, 6.5 million people in the US have Alzheimer’s disease as per 2022 data. As a result, the increased incidence of neurological illnesses across the world is driving the neuroscience antibodies and assays market forward.\n<\/p>\n

\nTechnological advancements are a key trend gaining popularity in the neuroscience antibodies and assays market. Major companies operating in the market are introducing new technologies such as Cisbio HTRF that works on TR-FRET technology to sustain their position in the market.\n<\/p>\n

\nFor instance, in October 2020, PerkinElmer Inc, a US-based diagnostics, life sciences, and environmental research company, launched ‘PerkinElmer Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit’. The new kit has applications in various disease areas such as Alzheimer’s and Parkinson’s disease. The novel assay’s can be applied to increase study specificity for the Phospho-Ubiquitin (Ser65) intersection point. With the help of TR-FRET technology helps to identify crucial mitophagy dysfunction and breakdowns in the intricate network between neurons and glial cells that can result in neurodegenerative disease.\n<\/p>\n

\nReasons to Purchase<\/strong>\n<\/p>\n